Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.
Despite global advancements in pediatric critical care, mortality and morbidity in septic shock remain unacceptably high. Although data suggest a reduction in mortality with steroid therapy in refractory shock, specific data for hydrocortisone in pediatrics are limited. The findings of this study would not only be a valuable addition to the existing stats but might also help develop a protocol for the use of hydrocortisone therapy in children with septic shock, seeking an earlier recovery from organ failure, earlier reversal of shock, and lower mortality in children with sepsis and septic shock.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
122
Children will receive early intravenous hydrocortisone at 2 mg/kg/day divided every 6 hours, continued for 7 days or until resolution of shock.
The children will be managed by following standard institutional treatment protocol.
Abbasi Shaheed Hospital
Karachi, Sindh, Pakistan
Mortality
The mortality will be labeled 'yes' if a patient dies within 28 days of admission.
Time frame: 28 days
Duration of vasopressor
Vasopressor therapy time will be computed from the start of treatment until hemodynamic stability is attained.
Time frame: 28 days
Length of pediatric intensive care unit stay
The time will be calculated from admission in the pediatric intensive care unit until discharge or mortality.
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.